The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

The present disclosure relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.

The present invention relates to the field of display technologies, and particularly to a fused polycyclic compound, and a preparation method and use thereof. The fused polycyclic compound provided in the present invention has a structure of General Formula IV. The structure of the compound has ambipolarity, and the HOMO level and the LUMO level of the host material are respectively located on different electron donating group and electron withdrawing group, such that the transport of charges and holes in the host material becomes more balanced, thereby expanding the area where holes and electrons are recombined in the light emitting layer, reducing the exciton concentration, preventing the triplet-triplet annihilation of the device, and improving the efficiency of the device.

The present invention relates to the field of display technologies, and particularly to a fused polycyclic compound, and a preparation method and use thereof. The fused polycyclic compound provided in the present invention has a structure of General Formula IV. The structure of the compound has ambipolarity, and the HOMO level and the LUMO level of the host material are respectively located on different electron donating group and electron withdrawing group, such that the transport of charges and holes in the host material becomes more balanced, thereby expanding the area where holes and electrons are recombined in the light emitting layer, reducing the exciton concentration, preventing the triplet-triplet annihilation of the device, and improving the efficiency of the device.

Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.

##STR00001##

A light-emitting device includes a hole blocking layer including one or more of compounds shown in following formula (1)a and formula (1)b.

##STR00001##

Z.sub.1 to Z.sub.11 are selected from H or R. R, R.sub.1 and R.sub.2 are each selected independently from deuterium, halogen, cyano, nitryl, amino, C.sub.1-C.sub.40 alkyl, C.sub.2-C.sub.40 alkenyl, C.sub.2-C.sub.40 alkynyl, C.sub.3-C.sub.40 cycloalkyl, C.sub.3-C.sub.40 heterocycloalkyl, C.sub.6-C.sub.60 aryl, C.sub.5-C.sub.60 heteroaryl, C.sub.1-C.sub.40 alkoxy, C.sub.6-C.sub.60 aryloxy, C.sub.3-C.sub.40 alkylsilyl, C.sub.6-C.sub.60 arylsilyl, C.sub.1-C.sub.40 alkylboron, C.sub.6-C.sub.60 arylboron, C.sub.6-C.sub.60 arylphosphinylene, C.sub.6-C.sub.60 monoaryl or diaryl phosphino and C.sub.6-C.sub.60 arylamino. R.sub.3 is selected from heterocyclyl and fused heterocyclyl.

This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

The present disclosure provides an organic compound, an organic electroluminescence device and an electronic apparatus. A chemical structure of the organic compound in the present disclosure contains an adamantane spirofluorene ring and a dibenzo five-membered ring. The organic compound has an excellent energy transfer function and can be used as a luminescent layer material in an electroluminescent device, thus improving an efficiency of the organic electroluminescence device and increasing a service life of the organic electroluminescence device.

The present disclosure provides an organic compound, an organic electroluminescence device and an electronic apparatus. A chemical structure of the organic compound in the present disclosure contains an adamantane spirofluorene ring and a dibenzo five-membered ring. The organic compound has an excellent energy transfer function and can be used as a luminescent layer material in an electroluminescent device, thus improving an efficiency of the organic electroluminescence device and increasing a service life of the organic electroluminescence device.

A compound comprising a ligand L.sub.A, having a structure of Formula I, ##STR00001##
is provided. In Formula I, A.sup.1 to A.sup.8 are each independently CR or N; at least two adjacent ones of A.sup.1 to A.sup.8 are CR and the Rs are joined together to form a six-membered ring fused to ring A or ring C; X is O, S, or Se; each R and R.sup.B is independently hydrogen or a substituent; any adjacent substituents are optionally joined or fused into a ring; the ligand L.sub.A is coordinated to a metal M; the metal M is bonded to ring A through a M-C bond; the metal M can be coordinated to other ligands; and the ligand L.sub.A is optionally linked with other ligands. Formulations, OLEDs, and consumer products containing such compounds are also disclosed.